Search

Controlling the grain size of steels is an effective way for tailoring their mechanical properties, such as yield strength, impact toughness, and ductility. In this study, a new industrial thermomechanical treatment was applied to a low-alloyed TRIP-assisted bainitic steel 13MnSiCr7 to achieve a substantial microstructural refinement. In this way the average grain size of the new micro-bainitic steel was decreased from ~25 µm to ~5 µm. Fatigue tests were carried out in order to investigate the influence of this new thermomechanical treatment on crack propagation behavior. Besides electron backscatter diffraction (EBSD), vibrating sample magnetometry (VSM), and high-energy synchrotron X-ray diffraction (HEXRD) were used to study the microstructure in the vicinity of the fatigue crack tip. The applicability of each method for detecting the martensitic transformation is discussed. In addition, the contribution of the martensitic transformation to fracture toughness was assessed on the basis of the results obtained by HEXRD., Peer Reviewed, Postprint (published version)

BACKGROUND AND AIMS: The long-term safety and efficacy of allogeneic bone marrow-derived mesenchymal stromal cell [bmMSC] therapy in perianal Crohn's disease [CD] fistulas is unknown. We aimed to provide a 4-year clinical evaluation of allogeneic bmMSC treatment of perianal CD fistulas. METHODS: A double-blind dose-finding study for local bmMSC therapy in 21 patients with refractory perianal fistulising Crohn's disease was performed at the Leiden University Medical Center in 2012-2014. All patients treated with bmMSCs [1 x 107 bmMSCs cohort 1, n = 5; 3 × 107 bmMSCs cohort 2, n = 5; 9 × 107 bmMSCs cohort 3, n = 5] were invited for a 4-year evaluation. Clinical events were registered, fistula closure was evaluated, and anti-human leukocyte antigen [HLA] antibodies were assessed. Patients were also asked to undergo a pelvic magnetic resonance imaging [MRI] and rectoscopy. RESULTS: Thirteen out of 15 patients [87%] treated with bmMSCs were available for long-term follow-up. Two non-MSC related malignancies were observed. No serious adverse events thought to be related to bmMSC therapy were found. In cohort 2 [n = 4], all fistulas were closed 4 years after bmMSC therapy. In cohort 1 [n = 4] 63%, and in cohort 3 [n = 5] 43%, of the fistulas were closed, respectively. In none of the patients anti-HLA antibodies could be detected 24 weeks and 4 years after therapy. Pelvic MRI showed significantly smaller fistula tracts after 4 years. CONCLUSIONS: Allogeneic bmMSC therapy for CD-associated perianal fistulas is also in the long-term a safe therapy. In bmMSC-treated patients, fistulas with closure at Week 24 were still closed after 4 years.